After pausing work on a rare cancer asset, Relay Therapeutics is passing the baton to Elevar Therapeutics. The two have ...

Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven ...

Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

Philips and the Mayo Clinic have launched a new research collaboration focused on applying artificial intelligence to MRI ...

Siemens Healthineers is rolling out artificial intelligence programs through its ultrasound platforms that automatically ...

Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French ...

Three compounds isolated from tuberculosis’s fungal foes killed cultured cells of the bacterium that causes the disease in ...

Kinevant Sciences, a Roivant spinout designed to test an investigational monoclonal antibody, has reported that the asset ...

Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 ...